ERBITUX PI PDF

April 2, 2019 posted by

treated with Erbitux and radiation therapy and in 3% of patients Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation- positive colorectal. Each mL of solution for infusion contains 5 mg cetuximab. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck All sections. PI reformatted.

Author: Yorg Kagataxe
Country: Tajikistan
Language: English (Spanish)
Genre: Business
Published (Last): 2 July 2012
Pages: 36
PDF File Size: 2.90 Mb
ePub File Size: 18.97 Mb
ISBN: 382-8-72286-333-1
Downloads: 28296
Price: Free* [*Free Regsitration Required]
Uploader: Shakagul

Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin. Nevertheless, regulation of serum magnesium also depends on gastrointestinal absorption, and an effect of EGFR inhibition on this process cannot be excluded at the present time. The risk or severity of adverse effects can be increased when Cetuximab is combined with Teprotumumab.

Rontalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Rontalizumab. Clinical manifestations of hypomagnesemia may occur gradually or suddenly, and include cardiac arrhythmias, seizures, and other electrolyte abnormalities eg, hypokalemia Whang et al ; Iannello and Belfiore Due to the potential for serious adverse reactions in breastfed infants from Erbitux, advise women not to breastfeed during treatment with Erbitux and for 2 months after the last dose of Erbitux.

However, because of its long elimination half-life — 4—5 days at steady-state ERBITUX PI — it is possible to administer cetuximab every 2 weeks and thereby improve patient convenience.

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anticancer monoclonal antibodies.

Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Impact of EGFR expression on colorectal cancer patients prognosis and survival.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Ustekinumab. Estriol Estriol may increase the thrombogenic activities of Cetuximab. Instruct patients to limit sun exposure during Erbitux therapy. Acneiform rash usually developed within the first two weeks of therapy; the rash lasted more than 28 days after stopping Erbitux in most patients.

  HURSTON THE GILDED SIX BITS PDF

No effects of cetuximab eritux observed on measured male fertility parameters i.

The risk or severity of adverse effects can be increased when Cetuximab erbtux combined with Human cytomegalovirus immune globulin. Importantly, adding cetuximab to irinotecan did not exacerbate toxicity, except for acne-form rash. The risk or severity of adverse effects can be increased when Cetuximab is combined with Palivizumab. Cetuximab is still given on a weekly basis when used in combination with bi-weekly chemotherapy regimens, such as FOLFIRI and FOLFOX, but additional alternative schedules can be optimized to make cetuximab administration more flexible, and perhaps easier to coordinate with those cytotoxic regimens.

Sulesomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sulesomab. The risk or severity of adverse effects erbituz be increased when Cetuximab is pk with Tralokinumab.

Tremelimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tremelimumab. Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and neck receiving Erbitux with radiation therapy or a cetuximab product with platinum-based therapy and fluorouracil.

Certolizumab pegol The risk or severity of adverse effects can be increased when Cetuximab is combined with Certolizumab pegol. The risk or severity of po effects can be increased when Cetuximab is combined with Tabalumab.

Ongoing studies are exploring whether cetuximab may be useful earlier in the course of disease in the adjuvant and neoadjuvant settings. Volociximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Volociximab.

Cetuximab in the management of colorectal cancer

The risk or severity of adverse effects can be increased when Cetuximab is combined with Benralizumab. These receptor polymorphisms have different affinities for their target Fc domains, which would be expected to translate into different levels of ADCC activity, and ultimately impact clinical response.

  BRUCE TIMM NAUGHTY AND NICE PDF

Disruption or depletion of EGFR in animal models results in impairment of embryo-fetal development including effects on placental, lung, cardiac, skin, and neural development.

Basiliximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Basiliximab. Fresolimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fresolimumab. Tibolone Tibolone may increase the thrombogenic activities of Cetuximab.

The onset of symptoms occurred between the fourth and eleventh doses of treatment in all reported cases. Lebrikizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lebrikizumab.

The incidence of Grade 3 or 4 late radiation toxicities was similar between the radiation therapy alone and the Erbitux with radiation treatment groups. The risk or severity of adverse effects can be increased when Cetuximab is combined with XmAb Lievre and coworkers Lievre et al recently reported that tumors with mutations in the K-Ras gene are associated with resistance to cetuximab therapy. If no improvement in 2 weeks or interstitial lung disease ILD is confirmed, discontinue Erbitux.

Medically reviewed on Jun 1, Mirvetuximab Soravtansine The risk or severity of adverse effects can be increased when Cetuximab is combined with Mirvetuximab Soravtansine.

Cetuximab – DrugBank

Infusion reactions may occur during therapy with monoclonal antibodies and cytotoxics Lenz Overall, 48 patients had normal magnesium levels before cetuximab treatment, and a repeat measurement of magnesium during treatment. The risk or severity of adverse effects can be increased when Cetuximab is combined with Lebrikizumab. The following sites were affected: The risk or severity of adverse effects can be increased when Cetuximab is combined with Bapineuzumab.

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.